The NIH-funded programme is expected to provide the NUZ-001 for patients who are otherwise ineligible for clinical trials access for up to 96 weeks
The acquisition is expected to accelerate GTBL's transition towards a globally integrated CDMO focused on fermentation and biotechnology-based manufacturing
Dengue vaccine expected to become available for eligible children and adults in the first half of 2027, subject to regulatory processes
He brings leadership experience in medical affairs from Dr. Reddy’s, Sanofi and Abbott
Global licensing deal valued at up to $314.8 million, alongside $2.2 million strategic equity investment
Jigani expansion to add biological buffer manufacturing, strengthen local production and regional supply chains
Shilpa Biologicals to retain IP and manufacturing rights, while Saudi Arabia’s SPIMACO Bio will lead commercialization, regulatory execution and market access across the region
With shared experience across oncology, inflammation and autoimmunity, the two companies will be able to contribute complementary scientific approaches within individual development programs
In-house developed and manufactured biosimilar marks company’s entry into immuno-oncology and aims to improve access to checkpoint inhibitor therapy
The formal collaboration with X-Chem will further strengthen Sygnature's ability to incorporate DEL screening into integrated drug discovery programs from August 2026
New module offers 7,000L reactor capacity and supports complex peptide APIs, while second module planning advances with customer requirements
Updated exploratory results from the Phase 3 ADAURA trial showed that Tagrisso reduced the risk of death by 47% compared with placebo in the primary population of patients with Stage II-IIIA disease
The combination brings together approximately 50 scientists across SCD’s Utrecht operations and TATAA Biocenter’s Gothenburg site, serving pharmaceutical, biotechnology and academic customers
The companies said the technology is intended to improve manufacturing productivity while supporting reliable and cost-effective processes as development programmes advance
The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab
The company said it has submitted its manufacturing, quality-control, reconciliation and distribution records to CDSCO on 14 August 2026 to support the investigation
The company said its growing experimental throughput requires digital infrastructure capable of rapidly converting large volumes of discovery data into actionable insights
Sheth brings extensive experience across contract development and manufacturing, drug discovery services, business development and strategic partnerships
The partnership is aimed at strengthening Cipla’s biosimilar portfolio and expanding access to advanced biologic therapies for cancer patients
Subscribe To Our Newsletter & Stay Updated
